Log In
Wednesday 21st March 2018

Vernalis to cut jobs

21st February 2008

Vernalis has unveiled plans to cuts its workforce by just over half after it became the latest casualty in the UK biotechnology sector.

Chief executive Simon Sturge also announced that he is to step down in a restructuring that will see Vernalis offload its US commercial operations along with one of its top selling drugs Apokyn, and cut its workforce from 210 to 90. Mr Sturge will not be replaced and the company will be run by executive chairman Peter Fellner.


Share this page


There are no comments for this article, be the first to comment!

Post your comment

Only registered users can comment. Fill in your e-mail address for quick registration.

Your email address:

Your comment will be checked by a Healthcare Today moderator before it is published on the site.

Mayden - Innovative cloud-based web development for the healthcare sector
© Mayden Foundation 2018